Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.
We previously demonstrated the substantial capacity for angiotensin (ANG) II formation in the interstitium of the dog heart in vivo. The current study tested the hypothesis that interstitial fluid (ISF) bradykinin (BK) is influenced by ANG II formation. Four microdialysis probes were inserted into the left ventricular myocardium of eight open-chest anesthetized dogs. The probe effluent was collected during four stages in each dog. Probes 1 and 3 sequentially delivered: 1) buffer; 2) ANG I (15 microM); 3) ANG II type 1 receptor antagonist (AT(1)-ant; irbesartan, 50 microM) or AT(2)-ant (PD123319, 50 microM); and 4) ANG I + AT(1)-ant or ANG I + AT(2)-ant. Probes 2 and 4 used the same protocol, substituting ANG II for ANG I in a concentration (0.5 microM) equivalent to that achieved during ANG I infusion. ISF BK levels increased 15-fold during ANG I (p < 0.001) but not during ANG II infusion. Co-infusion of selective AT(1)- and AT(2)-ants or nonselective AT-ant did not block the increase in ISF BK. ISF infusions of ANG I also produced a greater than 400-fold rise in ISF ANG-(1-7) over baseline. ISF infusion of ANG-(1-7) (10 microM) produced a 15-fold increase in ISF BK (p < 0.001). The metabolic machinery exists for the formation of BK and ANG-(1-7) in the cardiac ISF space that is not blocked by an AT receptor antagonist. The differential increase in ISF BK during ANG I and ANG-(1-7) but not during ANG II infusions suggests the possibility of decreased catabolism of ISF BK by an angiotensin-converting enzyme due to active site occupation by ANG I and ANG-(1-7).
Wei
Chih-Chang
CC
Birmingham Veteran Affairs Medical Center, Department of Medicine, Hypertension and Vascular Biology Program, University of Alabama, Birmingham 35294-0005, USA.
Ferrario
Carlos M
CM
Brosnihan
K Bridget
KB
Farrell
Diane M
DM
Bradley
Wayne E
WE
Jaffa
Ayad A
AA
Dell'Italia
Louis J
LJ
D000803:Angiotensin I / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001920:Bradykinin / Q000378:metabolism*; D004285:Dogs; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology; D017551:Microdialysis; D009206:Myocardium / Q000378:metabolism*; D010446:Peptide Fragments / Q000097:blood / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology
D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D010446:Peptide Fragments; D010455:Peptides; D011725:Pyridines; D000804:Angiotensin II; C073402:PD 123319; D000803:Angiotensin I; C118790:angiotensin I (1-7); D001920:Bradykinin